%%%%%%%%%%%% Program Specific Acronyms: %%%%%%%%%%%%%%%
% Program specific acronyms, such as disease, population, drugs, etc. are to be defined here
% Keep them separate from the general acronyms enables cleansing of project-specific info, if needed


%%%%%%%%%%%% General Acronyms: %%%%%%%%%%%%%%%
%General acronyms are to be defined here
%%%%%%%%% A
\newacronym{AAG}{AAG}{alpha-1-acid glycoprotein}
\newacronym{AIC}{AIC}{Akaike information criterion}
\newacronym{ALAG}{ALAG}{oral absorption lag time}
\newacronym{ALB}{ALB}{albumin}
\newacronym{ALT}{ALT}{alanine aminotransferase}
\newacronym{AST}{AST}{aspartate aminotransferase}
\newacronym[sort=AUC]{AUC}{AUC}{area under the concentration-time curve}
\newacronym[sort=AUCss]{AUCss}{AUC,ss}{area under the concentration-time curve for a dosing interval at steady-state condition}
\newacronym[sort=AUCC]{AUCC}{\ensuremath{AUC_{\mathrm{cumulative}}}}{cumulative area under the concentration-time curve since first dose}

%%%%%%%%% B
\newacronym{BIC}{BIC}{Bayesian information criterion}
\newacronym{BID}{BID}{twice daily}
\newacronym{BLQ}{BLQ}{below the limit of quantification}
\newacronym{BMI}{BMI}{body mass index}
\newacronym{BSA}{BSA}{body surface area}

%%%%%%%%% C
\newacronym{CATD}{CATD}{computer assisted clinical trial design}
\newacronym[sort=Cavg]{Cavg}{Cavg}{average concentration during the dosing interval}
\newacronym[sort=Cavgc]{Cavgc}{\ensuremath{C_{\mathrm{avg,\sim cumulative}}}}{average concentration since first dose calculated as $AUC_{\mathrm{cumulative}}$/TAFD}
\newacronym[sort=Cavgss]{Cavgss}{Cavg,ss}{average concentration during the dosing interval at steady-state}
\newacronym{CI}{CI}{confidence interval}
\newacronym[sort=CLi]{CLi}{CLi}{individual-specific systemic clearance}
\newacronym[sort=CLF]{CLF}{CL/F}{apparent clearance}
\newacronym[sort=Cmax]{Cmax}{Cmax}{maximum concentration in the dosing interval}
\newacronym[sort=Cmaxss]{Cmaxss}{Cmax,ss}{maximum concentration in the dosing interval at steady-state}
\newacronym[sort=Cmin]{Cmin}{Cmin}{minimum concentration in the dosing interval}
\newacronym[sort=Cminss]{Cminss}{Cmin,ss}{minimum concentration in the dosing interval at steady-state}
\newacronym{CRCL}{CRCL}{Cockroft-Gault calculated creatinine clearance based on total body weight}
\newacronym{CRP}{CRP}{C-reactive protein}
\newacronym{CP}{CP}{Child-Pugh}
\newacronym{CVP}{CV\%}{percent coefficient of variation}
\newacronym{CWRES}{CWRES}{conditional weighted residual}

%%%%%%%%% D
\newacronym{df}{df}{degrees of freedom}

%%%%%%%%% E
\newacronym{EBE}{EBE}{empirical Bayes estimate}
\newacronym{eGFR}{eGFR}{estimated Glomerular Filtration Rate}
\newacronym{EM}{EM}{expectation maximization}


%%%%%%%%% F
\newacronym[sort=F]{F}{F}{absolute bioavailability}
\newacronym{FDA}{FDA}{Food and Drug Administration}
\newacronym{FOCEI}{FOCEI}{first-order conditional estimation with $\eta$--$\epsilon$\ interaction}
\newacronym{FOCE}{FOCE}{first-order conditional estimation}
\newacronym{FPG}{FPG}{fasting plasma glucose}

%%%%%%%%% G
\newacronym{gh}{HbA1c}{glycosylated hemoglobin}

%%%%%%%%% H
\newacronym{hr}{hr}{hours}

%%%%%%%%% I
\newacronym{IBW}{IBW}{ideal body weight}
\newacronym{IC50}{IC50}{half maximal inhibitory concentration}
\newacronym{IGF-1}{IGF-1}{insulin-like growth factor 1}
\newacronym{IIV}{IIV}{interindividual variability}

%%%%%%%%% J

%%%%%%%%% K
\newacronym[sort=KA]{KA}{KA}{absorption rate constant}
\newacronym{kg}{kg}{kilograms}

%%%%%%%%% L
\newacronym{L}{L}{liters}
\newacronym{LL}{LL}{log likelihood}
\newacronym{LLQ}{LLQ}{lower limit of quantification}

%%%%%%%%% M
\newacronym{MAP}{MAP}{maximum a posteriori} 
\newacronym{mcg}{mcg}{micrograms}
\newacronym{mg}{mg}{milligrams}
\newacronym{mL}{mL}{milliliters}
\newacronym{MRG}{MRG}{mock receptor gate}
\newacronym{MS}{M\&S}{modeling and simulation}
\newacronym{MSP}{MSP}{modeling and simulation plan}

%%%%%%%%% N
\newacronym{ng}{ng}{nanograms}
\newacronym{NONMEM}{NONMEM}{nonlinear mixed effects modeling}
\newacronym[sort=N]{etai}{\ensuremath{\eta i}}{individual random effects}
\newacronym{NPDE}{NPDE}{normalized prediction distribution errors}


%%%%%%%%% O
\newacronym{OFV}{OFV}{objective function value}

%%%%%%%%% P
\newacronym{PD}{PD}{pharmacodynamic}
\newacronym{PK}{PK}{pharmacokinetics}
\newacronym{pg}{pg}{picograms}


%%%%%%%%% Q
\newacronym{QD}{QD}{once daily}
\newacronym[sort=QF]{QF}{Q/F}{apparent (oral) intercompartmental clearance}

%%%%%%%%% R
\newacronym{RES}{RES}{residuals}

%%%%%%%%% S
\newacronym{SCR}{SCR}{serum creatinine}
\newacronym{SD}{SD}{standard deviation}
\newacronym{ss}{ss}{steady-state}
\newacronym{SGLT}{SGLT}{sodium-dependent glucose cotransporters}

%%%%%%%%% T
\newacronym{TAD}{TAD}{time after most recent dose}
\newacronym{TAFD}{TAFD}{time after first dose}
\newacronym[sort=TVP]{TVP}{\ensuremath{\mathit{TVP}}}{typical value of a model parameter  $P$}
\newacronym{T2DM}{T2DM}{type 2 diabetes mellitus}
\newacronym[sort=t]{hl}{\ensuremath{t_{1/2}}}{elimination half-life}


%%%%%%%%% U
\newacronym{UKPDS}{UKPDS}{United Kingdom Prospective Diabetes Study}
 
%%%%%%%%% V
\newacronym[sort=VF]{VF}{V/F}{apparent volume of distribution}
\newacronym[sort=V1F]{V1F}{V1/F}{apparent volume of distribution}
\newacronym[sort=V2F]{V2F}{V2/F}{apparent central volume of distribution}
\newacronym[sort=V3F]{V3F}{V3/F}{apparent peripheral volume of distribution}
\newacronym{VPC}{VPC}{visual predictive check}

%%%%%%%%% W
\newacronym{WRES}{WRES}{weighted residuals}
\newacronym{WT}{WT}{weight}

%%%%%%%%% X
\newacronym[sort=X]{chi2}{\ensuremath{\chi^2}}{chi-squared distribution}


%%%%%%%%% Y

%%%%%%%%% Z

